The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

This is called summer-pattern SAD or summer depression, and it's not as common as winter ... at risk of developing winter blues or SAD if you have another mood disorder, such as major depressive ...

A compelling new study is building on a growing body of evidence showing a common exercise supplement used to build muscle ...

People with bipolar I disorder have had at least one manic episode preceded or followed by hypomanic or major depressive ...

(NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced two ...

The therapy scored a phase 2 win last year by showing that it significantly reduced depression severity among adults with major depressive disorder (MDD) who haven’t benefited from at least one ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...